Dexamethasone prodrug cyclodextrin aggregates effectively alleviate experimental autoimmune uveitis

Area of Science:

• Ophthalmology
• Pharmacology
• Drug Delivery

Background:

• Noninfectious uveitis (NIU) causes significant vision loss.
• Current glucocorticoid treatments have severe side effects like increased intraocular pressure and cataracts.
• Novel therapeutic strategies are needed to improve NIU management.

Purpose of the Study:

• To develop and evaluate dexamethasone gallate (DG) eye drops for NIU treatment.
• To assess the efficacy and safety of DG compared to conventional dexamethasone (DEX).
• To explore the combined anti-inflammatory and antioxidant properties of DG for ocular protection.

Main Methods:

• Synthesis of dexamethasone gallate (DG) prodrug.
• Formulation of DG into cyclodextrin microparticle suspension eye drops.
• Evaluation of DG eye drops in experimental autoimmune uveitis (EAU) models.

Main Results:

• DG eye drops showed comparable efficacy to DEX eye drops at lower doses in EAU models.
• DG significantly reduced anterior and posterior ocular inflammation.
• DG formulations minimized intraocular pressure elevation and adverse effects associated with glucocorticoids.

Conclusions:

• Dexamethasone gallate (DG) suspension eye drops represent a promising therapeutic alternative for NIU.
• DG offers a safer and more patient-friendly approach to managing noninfectious uveitis.
• The combined anti-inflammatory and antioxidant properties of DG enhance ocular tissue protection.